ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
Zevra Therapeutics (ZVRA) shares fell by 23% after the EMA’s CHMP issued a negative opinion on its application to market arimoclomol in Europe for Niemann-Pick disease type C. Despite this, H.C. Wainwright maintained its ‘Buy’ rating and $26 price target, stating that the setback is "not insurmountable" as Zevra plans to request a re-examination. The drug is already approved in the U.S. as MIPLYFFA and generated significant revenue in 2025.
Cash per share of Zevra Therapeutics, Inc. – HAN:1GDA
This article provides financial information for Zevra Therapeutics, Inc. (HAN:1GDA) from the Hannover Stock Exchange. It specifically highlights the "Cash per share" value, which is part of the company's financial overview available on the TradingView platform. The content is primarily a data point rather than an in-depth analysis.
Enterprise value to EBIT forward of Zevra Therapeutics, Inc. – HAN:1GDA
This article displays the "Enterprise value to EBIT forward" for Zevra Therapeutics, Inc. (1GDA) on the Hannover Stock Exchange. The market was closed at the time of publication, with no trades reported for this specific metric. The content emphasizes financial data and market information for the company.
Total debt per share of Zevra Therapeutics, Inc. – HAN:1GDA
This article provides the total debt per share information for Zevra Therapeutics, Inc. (HAN:1GDA) on the TradingView platform. It indicates that the market is closed with no trades recorded and highlights that the data is provided by ICE Data Services and FactSet.
Three New York conferences will feature Zevra leaders
Zevra Therapeutics (ZVRA) announced that its executive leadership team will present at three investor conferences in New York in September 2026. These conferences include the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of the fireside chats will be available on Zevra’s investor relations website, and management will also hold one-on-one meetings with registered attendees.
Zevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics announced that its executive leadership team will present at three upcoming investor conferences in New York, NY: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered attendees. Links to live webcasts will be available on the company's investor relations website.
Zevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics announced that its executive leadership team will present at three upcoming investor conferences in New York: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered attendees. Webcasts of the presentations will be accessible on Zevra's investor relations website.
Zevra Therapeutics to Present New Long-Term Real-World Data
Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) at the SSIEM Annual Symposium. The data, from U.S. and German early access programs, highlights sustained disease stabilization and a consistent safety profile across diverse NPC patient populations over several years. This reinforces the drug's effectiveness and safety, with some patients experiencing rapid clinical deterioration upon discontinuation.
A rare-disease drug has up to 8 years of real-world data. Zevra will present the findings.
Zevra Therapeutics will present new long-term real-world data on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium. The data, including up to 8 years of experience from U.S. expanded access and German compassionate use programs, show sustained disease stabilization across various patient populations and ages. MIPLYFFA is FDA-approved in the U.S. and has an EMA Marketing Authorization Application under review, with findings emphasizing its long-term safety and effectiveness in treating NPC.
Zevra Therapeutics to Present New Long-Term Real-World Data
Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) at the SSIEM Annual Symposium. The data, from U.S. and German early access programs, highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations over up to eight years of treatment. The presentations reinforce MIPLYFFA's effectiveness and safety, even noting clinical deterioration in patients who discontinued treatment.
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
Zevra Therapeutics (ZVRA) shares rallied 8% to a near five-year high after positive brokerage actions and the company's request to add a new patent for its Miplyffa drug to the FDA's Orange Book. Analysts from Citizens and Canaccord raised their price targets, citing extended market exclusivity for Miplyffa, which generated over 80% of Zevra's sales in 2025. Retail sentiment for ZVRA also turned "extremely bullish" on Stocktwits, with users predicting further price increases.
Zevra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced inducement grants of stock options to two new non-executive employees. These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The options have a ten-year term and vest over four years, subject to continued employment.
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) reported strong Q2 earnings of $0.25 per share, significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million, surpassing estimates by 22.76%. Despite this positive performance, the company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends prior to the earnings release. The stock has gained 17.4% year-to-date, outperforming the S&P 500.
Price to earnings forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA
This article provides the "Price to earnings forward" data for Zevra Therapeutics, Inc. (NASDAQ: ZVRA) as listed on TradingView. It appears to be a data point or financial metric for the company, accessible through their financial section on the platform. The content primarily consists of navigation and disclaimer text, with the core information being the financial metric itself.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics, Inc. announced that it has granted inducement awards consisting of options to purchase 92,200 shares of its common stock to four new employees. These awards vest over four years, with 25% on the first anniversary and the remainder in three equal annual installments, contingent on continued employment. The grants were approved by the Company's Compensation Committee and are in accordance with Nasdaq Rule 5635(c)(4).
Four new Zevra employees receive stock options that vest over four years
Zevra Therapeutics announced it granted stock options to purchase an aggregate of 92,200 common shares to four new employees. These inducement awards, approved by the Company's Compensation Committee, vest over four years, with 25% vesting after the first year and the remainder in three equal annual installments, contingent on continued employment. This action aligns with Nasdaq Rule 5635(c)(4) and is intended to incentivize new hires.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced it has granted inducement awards of 92,200 shares of common stock to four new employees under its 2023 Employment Inducement Award Plan. These awards vest over four years, with 25% on the first anniversary and the remainder in three equal annual installments, contingent on continued employment. The grants were approved by the Company’s Compensation Committee and serve as an inducement for the individuals to join Zevra, in compliance with Nasdaq Rule 5635(c)(4).
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright has reiterated its Buy rating for Zevra Therapeutics (ZVRA.US), maintaining a target price of $26. This indicates continued confidence from the analyst firm in the company's prospects.
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy
H.C. Wainwright reiterated a buy rating and a $26.00 price target for Zevra Therapeutics (NASDAQ: ZVRA) after an investor dinner, expressing increased confidence in the U.S. MIPLYFFA opportunity, potential European approval, and celiprolol as a future commercial asset. The firm noted Zevra's strong financial position with over $260 million in cash and investments and no debt. This follows Zevra's Q2 2026 results, which surpassed Wall Street expectations for both earnings and revenue, driven by strong MIPLYFFA sales.
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company recently reported strong quarterly earnings, beating both EPS and revenue estimates, and institutional investors hold a substantial stake in the stock.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages
Zevra Therapeutics (NASDAQ:ZVRA) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $27.14, significantly higher than its current share price of $11.57. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Institutional ownership is at 35.03%, though one director recently sold a substantial number of shares.
Zevra Therapeutics (ZVRA) insider sells 42,666 shares
Zevra Therapeutics (ZVRA) Chief Legal & Compliance officer, Rahsaan Thompson, sold 42,666 shares of common stock on August 14, 2026, through a Rule 10b5-1(c) trading plan. The sale was executed at a weighted average price of $11.1277 per share, with prices ranging from $10.86 to $11.36. Following this transaction, Thompson directly holds 37,569 shares of the company.
Price-Driven Insight from (ZVRA) for Rule-Based Strategy
This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short setup.
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker
An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous 10b5-1 sales by Rahsaan Thompson, including 34,557 common shares sold for over $438,000 in June 2026.
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position
Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is based on 59,115,084 shares of Zevra common stock outstanding as of May 1, 2026.
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics
Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, realizing a value of $77,859. The transaction was reported in an SEC filing on August 12. Zevra Therapeutics shows positive revenue trends with a 53.25% growth as of June 30, 2026, and strong financial metrics like a 96.16% gross margin and low debt-to-equity ratio, despite its market capitalization being below industry benchmarks.
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA
This article provides a financial overview of Zevra Therapeutics, Inc. (FWB:1GDA) on the Frankfurt Stock Exchange, focusing on its price-to-earnings forward metric. It highlights that the market is currently closed with no trades. The content is sourced from FactSet and ICE Data Services.
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics
Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, valued at $77,859, according to a recent SEC filing. The company's financials show a positive revenue trend with 53.25% growth, a high gross margin of 96.16%, but a declining EPS of 0.14. Despite ZVRA shares being down by 1.57% at $11.3 following the news, the company maintains a low debt-to-equity ratio and an impressive EV/EBITDA ratio.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (ZVRA) following a significant stock price drop. The investigation stems from the European Medicines Agency's negative opinion on Zevra's Marketing Authorization Application for arimoclomol, a drug for Niemann-Pick disease type C. Investors who suffered losses are encouraged to contact the firm.
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock
Zevra Therapeutics Director Corey Michael Watton sold 12,300 shares of the company's stock for $138,375.00, reducing his holdings by 87.23% to 1,800 shares. This transaction follows a strong quarterly earnings report where ZVRA exceeded both EPS and revenue estimates. Analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $27.14 despite one recent price target cut.
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA
Dimensional Fund Advisors LP significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 259.2% in the first quarter, purchasing an additional 400,336 shares to bring its total holdings to 554,802 shares valued at $5.168 million. Other institutional investors also adjusted their positions in Zevra Therapeutics, with several increasing their holdings. The article also provides an overview of Zevra Therapeutics' stock performance, recent earnings, and current analyst ratings, which average a "Moderate Buy."
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Zevra Therapeutics, Inc. (ZVRA) on behalf of investors who purchased its securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in Zevra's stock price. The firm encourages affected shareholders to connect through its website to assist with the investigation, which is conducted on a contingency fee basis.
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data
Zevra Therapeutics' stock (ZVRA) rose 21.6% following strong Q2 2026 sales of US$39.66 million, driven by high uptake of its Niemann-Pick disease type C therapy, MIPLYFFA. New four-year real-world data for arimoclomol (MIPLYFFA's active ingredient) could be crucial for European regulatory re-examination, potentially reshaping the investment narrative beyond recent negative headlines. Despite a low earnings multiple, the stock remains sensitive to regulatory decisions and MIPLYFFA's market momentum, with ongoing legal scrutiny posing a key risk.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings with registered attendees. A live webcast will be accessible via the company's investor relations website.
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?
Zevra Therapeutics (ZVRA) has released new long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C, aiming to support its equity story and regulatory efforts in Europe. This data will be crucial as the company seeks a re-examination of a negative EMA opinion. Investors are watching closely how the European Medicines Agency (EMA) responds to Zevra's request for re-examination, as regulatory decisions will impact the company's prospects for European revenue.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (NASDAQ: ZVRA) and its officers/directors. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding Zevra's Marketing Authorization Application for arimoclomol, which caused a significant drop in the company's stock price on July 24, 2026. Investors who believe they have been affected are encouraged to contact the firm.
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure
FMR LLC and Abigail P. Johnson have disclosed an 8.3% beneficial ownership stake in Zevra Therapeutics (ZVRA) through a Schedule 13G/A filing. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, while Abigail P. Johnson holds sole dispositive power over the same 4,915,717 shares, indicating her control relation to FMR LLC. This filing outlines the ownership structure and confirms that no other single person has an interest exceeding five percent of the outstanding common stock.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in the company's stock price. The firm encourages affected investors to contact them to assist with the investigation, which is conducted on a contingency fee basis.
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside
Zevra Therapeutics, Inc. (ZVRA) has seen its average 12-month price target increase from $24.78 to $25.11, according to estimates from nine analysts. This updated target implies a significant 138% potential upside from the August 5 closing price, with individual forecasts ranging from $20 to $35 per share. The consensus rating from all nine covering analysts remains a "Buy."
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) following a sharp drop in its stock price. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's Marketing Authorization Application for arimoclomol, branded Meplyffa. The firm encourages ZVRA stockholders to contact them to assist with the investigation, which is conducted on a contingency fee basis.
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54
Zevra Therapeutics (NASDAQ: ZVRA) appears significantly undervalued according to GuruFocus' GF Value™, trading at $10.54, which is 54.4% below its intrinsic value estimate of $23.11. Despite strong Q2 2026 revenue growth driven by its product MIPLYFFA, the company's GF Score™ of 64/100 indicates moderate overall quality with strong financial strength but weaker profitability and a "Possible Value Trap" caution. Insider selling transactions totaling $0.5 million in the past three months further suggest a nuanced investment profile requiring thorough due diligence.
Zevra Therapeutics Reports Strong Q2 2026 Earnings with Growth in MIPLYFFA
Zevra Therapeutics announced robust Q2 2026 earnings, reporting $39.7 million in net revenue, a 53% year-over-year increase, largely driven by $30.2 million in U.S. sales of MIPLYFFA. The company also strengthened MIPLYFFA's intellectual property with an Orange Book listing extending to 2041. Despite strong U.S. performance, Zevra faces challenges in Europe due to a negative CHMP opinion on arimoclomol, prompting a reexamination process.
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) reported strong Q2 results, with earnings of $0.25 per share significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million surpassing estimates by 22.76%. Despite this positive performance and a 17.4% year-to-date stock increase, the company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends. Investors are advised to monitor future estimate changes and management commentary for insights into the stock's future trajectory.
ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary
Zevra Therapeutics, Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $39.66M and diluted EPS of $0.14, primarily driven by the commercialization of MIPLYFFA. The company highlighted significant revenue growth, successful market penetration for MIPLYFFA, and ongoing progress in its clinical trials, alongside strategic financial and regulatory initiatives.
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics reported strong second-quarter 2026 financial results, with $39.7 million in net revenue, a 53% increase over Q2 2025, primarily driven by MIPLYFFA sales. The company achieved a net income of $8.8 million and maintained a robust cash position of $260.2 million, which it believes is sufficient to execute its strategic priorities without relying on capital markets. Zevra also provided updates on its pipeline, including progress in the DiSCOVER trial for celiprolol and ongoing efforts to gain European approval for arimoclomol.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will deliver the presentation, and management will also be available for one-on-one meetings with registered conference attendees. A live webcast of the presentation will be accessible on the "Events & Presentations” page of Zevra’s investor relations website.
Zevra executives set to present at Boston growth conference
Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast of the presentation will be accessible via the Investor Relations section of Zevra's website. The company, focused on rare diseases, plans to discuss its progress, pipeline, and efforts to broaden access to its life-changing therapies, including its lead product for Niemann-Pick disease type C.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will present and be available for one-on-one meetings with registered attendees. A live webcast link will be available on the Investor Relations section of Zevra’s website.
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky has initiated a securities investigation into Zevra Therapeutics (ZVRA) following a significant 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa. The investigation focuses on whether Zevra made misleading public statements regarding arimoclomol's approval status, specifically a May 2024 statement by CEO Neil McFarlane.
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has issued a securities investigation notice for Zevra Therapeutics (NASDAQ: ZVRA) following a 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. The investigation focuses on potential misstatements made by Zevra, particularly a May 2024 earnings call statement by CEO Neil McFarlane regarding arimoclomol's anticipated status as the "only approved foundational therapy" for NPC.
